Related Experiment Video
Updated: Jun 26, 2026
08:34
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Pulmonary hypertension in chronic heart failure
D Bonderman1, A M Martischnig, D Moertl
1Department of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, Austria. diana.bonderman@meduniwien.ac.at
International Journal of Clinical Practice. Supplement
|January 31, 2009
Summary
Pulmonary hypertension (PH) in congestive heart failure (CHF) is common and linked to poor outcomes. Current treatment lacks standardized definitions and proven long-term benefits, necessitating further research.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Heart Failure Research
Background:
- Pulmonary hypertension (PH) frequently complicates congestive heart failure (CHF) and is associated with adverse prognoses.
- Current understanding and management of PH in CHF, particularly 'out-of-proportion' PH, are limited by a lack of precise definitions and standardized diagnostic protocols.
- Large-scale trials demonstrating long-term efficacy of pulmonary vasoactive drugs in this specific patient group are absent.
Purpose of the Study:
- To highlight the clinical challenges and knowledge gaps in managing pulmonary hypertension associated with left heart disease.
- To emphasize the need for standardized definitions and diagnostic approaches for PH in CHF.
- To underscore the requirement for evidence-based treatment strategies and further clinical trials for PH in CHF patients.
Main Methods:
- Review of current literature and clinical guidelines regarding PH in CHF.
- Analysis of existing data on the prevalence and prognostic implications of PH in CHF.
- Identification of limitations in current diagnostic and therapeutic strategies.
Main Results:
- Pulmonary hypertension is a common comorbidity in CHF, predicting poor patient outcomes.
- Standardized definitions and vasodilator testing protocols for PH in CHF are currently lacking.
- No large-scale trials have confirmed long-term benefits of pulmonary vasoactive drugs for PH in CHF, leading to discouragement of off-label use.
Conclusions:
- Treatment of the underlying left heart disease is the primary approach to reduce pulmonary pressures in most CHF patients with PH.
- There are no consensus recommendations for treating PH in the setting of CHF due to insufficient evidence.
- Further clinical trials focusing on 'out-of-proportion' PH in CHF patients are essential, especially with the development of novel therapeutic agents.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...